RECRUITING

PCS in Severe Treatment Resistant Depression

Conditions

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

This research study is designed to test if electrical stimulation of the surface of the brain in the frontal region will help treat depressive symptoms. Participants receive intermittent electrical stimulation to the brain, which involves surgically placing electric leads in between the tough fibrous membrane covering the surface of the brain and the surface of the brain itself. This type of stimulation is referred to as bilateral subdural prefrontal cortical stimulation (PCS) because it will specifically target the outer layer of the brain at the midline, right behind the forehead. It uses a pacemaker-like device, the Proclaim Elite SCS System (non-rechargeable) or the Eterna SCS System (rechargeable), both by Abbott Laboratories for stimulation. Although the U.S. Food and Drug Administration (FDA) has approved the Proclaim Elite SCS system for brain stimulation for patients with chronic pain and muscular diseases, such as Parkinson's, its use is still investigational, and the surgery is still experimental for patients who have depression.

Official Title

Prefrontal Cortical Stimulation (PCS) for Severe Treatment Resistant Depression

Quick Facts

Study Start:2021-09-29

Study Completion:2027-12-31

Study Type:Not specified

Phase:Not Applicable

Enrollment:Not specified

Status:RECRUITING

Study ID

NCT04124341

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:22 Years to 70 Years

Sexes Eligible for Study:ALL

Accepts Healthy Volunteers:No

Standard Ages:ADULT, OLDER_ADULT

Inclusion Criteria	Exclusion Criteria
* Participant must be able to provide written informed consent. * Participant has a diagnosis of chronic (greater than or equal to 2 years) depressive episode as defined by DSM V criteria * Participant has not had an adequate response to four or more adequate antidepressant treatments from at least two different antidepressant treatment categories in the current depressive episode according to the Antidepressant Treatment History Form (ATHF) * Participant must have had ECT (Electroconvulsive Therapy) or refused to undergo ECT if clinically indicated to them * Participant must have HRSD greater than or equal to 20 at study entry * Participant must be able to complete the evaluations needed for this study including the functional imaging scans and the EEG Bayesian optimization sessions * Participant must be under the care of a licensed psychiatrist, undergoing regular care evaluations, and inform study team of any change to care team during study participation * Participant must agree to allow all forms of communication between investigators and study staff and any health care provider (current or having provided service within two years of enrollment) * Participant must provide name and contact information for at least two people greater than or equal to 22 in age who reside within a 30 minute drive of the participant's residents and whom staff may contact as necessary during study participation * Participant must be enrolled in a Medicare program	* The PCS would (in the investigator's judgment) pose an unacceptable surgical or medical risk for the participant * Participant is unable to undergo required full body magnetic resonance imaging (MRI) during the clinical study * Participant is judged by the investigator to be acutely suicidal (e.g. within the 30 days prior to the PCS implant the participant has made a suicide attempt or gesture or has made specific plans or preparation to commit suicide or scores 21 or higher on the MSSI) * In addition to the acute suicidal risks mentioned above, participant meets any of the following: 1. Has made a suicide attempt within the previous 12 months that required medical treatment 2. Has made greater than or equal to two suicide attempts in the past 12 months 3. Has a clear-cut plan for suicide that states that she/he cannot guarantee that she/he will call her/his regular psychiatrist or the Investigator if the impulse to implement the plan becomes substantial during the study 4. Is likely to attempt suicide within the next six months, in the Investigator's opinion * Participant has a history of schizophrenia, schizoaffective disorder, or other psychotic disorder, or a current major depressive episode that includes psychotic features (commonly referred to as psychotic depression) according to the DSM V criteria * Participant with a diagnosis of dementia with a Mini-Mental State Exam (MMSE) less than or equal to 23 * Participant with a positive urine pregnancy test * Participant with a positive urine drug screen * Participant with DBS (Deep Brain Stimulator) * Participant with VNS (Vagus Nerve Stimulator) if the device was active in the last 6 months prior to study enrollment * Participant with history of seizures * Participant determined by surgical safety committee to have cerebral atrophy, neurodegenerative or neurovascular disease due to age or medical condition that would prohibit optimal surgical safety, per clinical MRI

Inclusion Criteria

Exclusion Criteria

* Participant must be able to provide written informed consent.
* Participant has a diagnosis of chronic (greater than or equal to 2 years) depressive episode as defined by DSM V criteria
* Participant has not had an adequate response to four or more adequate antidepressant treatments from at least two different antidepressant treatment categories in the current depressive episode according to the Antidepressant Treatment History Form (ATHF)
* Participant must have had ECT (Electroconvulsive Therapy) or refused to undergo ECT if clinically indicated to them
* Participant must have HRSD greater than or equal to 20 at study entry
* Participant must be able to complete the evaluations needed for this study including the functional imaging scans and the EEG Bayesian optimization sessions
* Participant must be under the care of a licensed psychiatrist, undergoing regular care evaluations, and inform study team of any change to care team during study participation
* Participant must agree to allow all forms of communication between investigators and study staff and any health care provider (current or having provided service within two years of enrollment)
* Participant must provide name and contact information for at least two people greater than or equal to 22 in age who reside within a 30 minute drive of the participant's residents and whom staff may contact as necessary during study participation
* Participant must be enrolled in a Medicare program

* The PCS would (in the investigator's judgment) pose an unacceptable surgical or medical risk for the participant
* Participant is unable to undergo required full body magnetic resonance imaging (MRI) during the clinical study
* Participant is judged by the investigator to be acutely suicidal (e.g. within the 30 days prior to the PCS implant the participant has made a suicide attempt or gesture or has made specific plans or preparation to commit suicide or scores 21 or higher on the MSSI)
* In addition to the acute suicidal risks mentioned above, participant meets any of the following:
1. Has made a suicide attempt within the previous 12 months that required medical treatment
2. Has made greater than or equal to two suicide attempts in the past 12 months
3. Has a clear-cut plan for suicide that states that she/he cannot guarantee that she/he will call her/his regular psychiatrist or the Investigator if the impulse to implement the plan becomes substantial during the study
4. Is likely to attempt suicide within the next six months, in the Investigator's opinion
* Participant has a history of schizophrenia, schizoaffective disorder, or other psychotic disorder, or a current major depressive episode that includes psychotic features (commonly referred to as psychotic depression) according to the DSM V criteria
* Participant with a diagnosis of dementia with a Mini-Mental State Exam (MMSE) less than or equal to 23
* Participant with a positive urine pregnancy test
* Participant with a positive urine drug screen
* Participant with DBS (Deep Brain Stimulator)
* Participant with VNS (Vagus Nerve Stimulator) if the device was active in the last 6 months prior to study enrollment
* Participant with history of seizures
* Participant determined by surgical safety committee to have cerebral atrophy, neurodegenerative or neurovascular disease due to age or medical condition that would prohibit optimal surgical safety, per clinical MRI

Contacts and Locations

Study Contact

Ziad Nahas, MD, MSCR

CONTACT

952-525-4505

znahas@umn.edu

Rachel Johnson, PhD

CONTACT

952-525-4505

ipl@umn.edu

Principal Investigator

Ziad Nahas, MD

PRINCIPAL_INVESTIGATOR

University of Minnesota

Study Locations (Sites)

University of Minnesota

Minneapolis, Minnesota, 55455

United States

Collaborators and Investigators

Sponsor: University of Minnesota

Ziad Nahas, MD, PRINCIPAL_INVESTIGATOR, University of Minnesota

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2021-09-29

Study Completion Date2027-12-31

Study Record Updates

Study Start Date2021-09-29

Study Completion Date2027-12-31

Terms related to this study

Additional Relevant MeSH Terms

Treatment Resistant Depression